Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
8.25
+0.07 (0.86%)
At close: Dec 20, 2024, 4:00 PM
8.27
+0.02 (0.24%)
After-hours: Dec 20, 2024, 7:53 PM EST
Altimmune Employees
Altimmune had 59 employees as of December 31, 2023. The number of employees increased by 7 or 13.46% compared to the previous year.
Employees
59
Change (1Y)
7
Growth (1Y)
13.46%
Revenue / Employee
$881
Profits / Employee
-$1,754,576
Market Cap
586.78M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Cross Country Healthcare | 13,131 |
Varex Imaging | 2,300 |
GRAIL | 1,360 |
Fulgent Genetics | 1,184 |
Surmodics | 389 |
Simulations Plus | 247 |
Omeros | 198 |
Capricor Therapeutics | 102 |
ALT News
- 2 days ago - Altimmune Added to Nasdaq Biotechnology Index - GlobeNewsWire
- 6 days ago - Altimmune 2025: Redefining Obesity And MASH Treatment - Seeking Alpha
- 25 days ago - Altimmune to Participate at Two Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - GlobeNewsWire
- 5 weeks ago - Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge - Seeking Alpha
- 5 weeks ago - Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health - Seeking Alpha
- 5 weeks ago - Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire